Investment Banks Initiates Promising Price Target For Biotech Stock
Purple Biotech: A Promising Investment Frontier as Chardan Capital Maintains $11 Price Target.
As we delve into the dynamic world of biotechnology, one name that stands out is Purple Biotech Ltd - ADR ($PPBT). This Israel-based clinical-stage company has been given a 'Buy' rating by Chardan Capital, a globally renowned investment bank specializing in healthcare, SPACs, and other emerging growth companies. The bank has maintained a price target of $11 for the company's American Depositary Receipts (ADRs), a figure significantly higher than its current trading price of $.7959. $Purple Biotech (PPBT.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
